{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:05:11Z","timestamp":1774418711410,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04078-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:12:33Z","timestamp":1761721953000},"page":"1384-1393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of high-risk prostate cancer in Spain: results from a national patterns of care survey"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-8176","authenticated-orcid":false,"given":"Victor","family":"Duque-Santana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonia","family":"G\u00f3mez-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrahams","family":"Ocanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias Gomis","family":"Selles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miren","family":"Gazta\u00f1aga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Willisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier Maldonado","family":"Pijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Luis","family":"Blanco-Villar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Henriquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Carlos","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivone","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alai Go\u00f1i","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta L\u00f3pez","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio Visus Fern\u00e1ndez","family":"de Manzanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana P\u00e9rez","family":"Echag\u00fcen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar Alonso","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Vera","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Velilla","family":"Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Illescas","family":"Vacas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar Mar\u00eda Samper","family":"Ots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alberto","family":"Glar\u00eda Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel Montero","family":"Luis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Montezuma","family":"Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"del Castillo Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edsabet Gonz\u00e1lez","family":"Del Portillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Jos\u00e9","family":"Conde Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Del Cerro Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"URONCOR investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"4078_CR1","unstructured":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. EAU (European Association of Urology) [Internet]. 2025. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"issue":"8","key":"4078_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol"},{"issue":"17","key":"4078_CR3","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397.","journal-title":"J Clin Oncol"},{"issue":"20","key":"4078_CR4","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1200\/JCO.23.02445","volume":"42","author":"WR Lee","year":"2024","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Long-term analysis of NRG oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2024;42(20):2377\u201381. https:\/\/doi.org\/10.1200\/JCO.23.02445.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4078_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","volume":"106","author":"KC De Vries","year":"2020","unstructured":"De Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2020;106(1):108\u201315. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4078_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4078_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","volume":"103","author":"PJ Hoskin","year":"2012","unstructured":"Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217\u201322. https:\/\/doi.org\/10.1016\/j.radonc.2012.01.007.","journal-title":"Radiother Oncol"},{"key":"4078_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ctrv.2018.10.004","volume":"70","author":"DLC Kee","year":"2018","unstructured":"Kee DLC, Gal J, Falk AT, Schiappa R, Chand ME, Gautier M, et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev. 2018;70:265\u201371. https:\/\/doi.org\/10.1016\/j.ctrv.2018.10.004.","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"4078_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391(15):1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med"},{"issue":"10196","key":"4078_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet"},{"key":"4078_CR11","doi-asserted-by":"publisher","unstructured":"Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, et al. PACE Investigators. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025;26(7):936-947. https:\/\/doi.org\/10.1016\/S1470-2045(25)00205-0","DOI":"10.1016\/S1470-2045(25)00205-0"},{"issue":"3","key":"4078_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","volume":"110","author":"R van Dams","year":"2021","unstructured":"van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, et al. Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys. 2021;110(3):731\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.016.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4078_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","volume":"103","author":"D Dearnaley","year":"2019","unstructured":"Dearnaley D, Griffin CL, Lewis R, Mayles P, Mayles H, Naismith OF, et al. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). Int J Radiat Oncol Biol Phys. 2019;103(3):605\u201317. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.10.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4078_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234\u201342. https:\/\/doi.org\/10.1200\/JCO.20.03282.","journal-title":"J Clin Oncol"},{"key":"4078_CR15","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. 2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"10231","key":"4078_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"3","key":"4078_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","volume":"79","author":"NK Jairath","year":"2021","unstructured":"Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021;79(3):374\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.021.","journal-title":"Eur Urol"},{"key":"4078_CR18","doi-asserted-by":"publisher","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) Investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447-460. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5","DOI":"10.1016\/S0140-6736(21)02437-5"},{"issue":"4","key":"4078_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4078_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MOU.0000000000001313","volume":"35","author":"UG Falagario","year":"2025","unstructured":"Falagario UG, Pellegrino F, Wiklund P. Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy? Curr Opin Urol. 2025;35(5):499\u2013505. https:\/\/doi.org\/10.1097\/MOU.0000000000001313.","journal-title":"Curr Opin Urol"},{"issue":"12","key":"4078_CR21","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1016\/j.clon.2023.09.012","volume":"35","author":"JD Subiela","year":"2023","unstructured":"Subiela JD, GomisSell\u00e9s E, Maldonado A, Lopez Campos F, AumatellOvide J, Illarramendi A, et al. Clinical usefulness of prostate-specific membrane antigen-ligand positron emission tomography\/computed tomography for the detection of prostate cancer biochemical recurrence after primary radiation therapy in patients with prostate-specific antigen below the Phoenix threshold: systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2023;35(12):e676\u201388. https:\/\/doi.org\/10.1016\/j.clon.2023.09.012.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"4078_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","volume":"80","author":"LF Valle","year":"2021","unstructured":"Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021;80(3):280\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.010.","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04078-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:13:34Z","timestamp":1774415614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04078-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4078"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04078-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct affiliation 2.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}